Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novel Screening Method Yields New Class of Anti-Cancer Drugs

By Ryan Bushey | December 21, 2016

Scientists from the Scripps Research Institute created an efficient screening process that can quickly find new “enediyne natural products,” which are essentially promising drug leads derived from soil microbes.

The team, led by TSRI professor Ben Shen, Ph.D., used this technique to identify a new group of enediyne natural products named tiancimycins. These products can kill certain cancer cells more quickly and completely than the monoclonal antibodies used in conjunction with cytotoxic drugs that target only cancer cells, according to the official announcement.

“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” said Shen in a statement. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”

Essentially, Shen’s method involved prioritizing the microbial strains that could produce the most important natural compounds enabling a more efficient allocation of resources during the discovery process. 

Other researchers have used similar methods to sift through large amounts of data in order to pinpoint promising compounds to treat diseases.

A team at the Broad Institute of MIT and Harvard performed a similar process where they searched through a large chemical compound database for experimental malaria drugs with previously unknown novel mechanisms of action.

Shen and his colleagues published their work in the journal mBIO.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50